Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: liver + cancer + search  Related to the article below (Last Update: 8/5/2008)

Pasig hospital offers fresh hope to liver cancer patients
Inquirer.net, Philippines - Aug 1, 2008
By Beverly T. Natividad MANILA, Philippines ? A new technology introduced recently in the Philippines offers new hope to Filipinos with liver cancer, ...
Low radiation exposure tied to cancer risk
The Daily Yomiuri, Japan -
The risks of suffering from liver cancer were 1.73 to 2.4 times higher for men in the area and 1.9 to 2.65 times higher for women in the area. ...
Marshall Woman Battles Flood Rebuilding, Liver Cancer
WISC, WI - Aug 3, 2008
Since last fall, Gullixson has been fighting liver cancer, a battle she's resigned to losing. Her family has stood by her, but when the floods came, ...

eFluxMedia
Onyx and Bayer's liver cancer drug OK'd in China
Bizjournals.com, NC - Jul 28, 2008
China -- home of the world's largest number of liver patients -- approved a liver cancer drug from Onyx Pharmaceuticals Inc. of Emeryville and Bayer ...
Onyx gets Chinese approval for liver cancer drug Forbes
Nexavar Approved for Liver Cancer in China FOXBusiness
China reports half of world's new liver cancer cases Xinhua
Bizjournals.com - Forbes
all 62 news articles »  ONXX - OTC:BAYRY - OTC:CMTX
Sorting Out Coffee?s Contradictions
New York Times, United States -
In fact, another review suggested that compared with people who do not drink coffee, those who do have half the risk of developing liver cancer. ...
Nastech Pharmaceutical Company Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha, NY -
One additional distinction of our formulation is that we have demonstrated knockdown of ApoB message RNA in the non-liver organ in which it is synthesized, ...MRNA
Penn researchers find a new role for a 'Foxy Old Gene'
Hindu, India - Aug 3, 2008
PSC is associated with an increased risk of liver cirrhosis and liver cancer. Biliary atresia is a birth defect in which the bile ducts do not have normal ...

Chatter Shmatter
Targeted Drug Boosts Survival Among Liver Cancer Patients
Washington Post, United States - Jul 23, 2008
By Serena Gordon WEDNESDAY, July 23 (HealthDay News) -- The drug Nexavar can prolong the lives of people with liver cancer by an average of three months, ...
Anti-cancer drug extends life of liver cancer patients CTV.ca
Nexavar Works for Liver Cancer, But It Isn?t Cheap Wall Street Journal Blogs
Nexavar Improves Liver Cancer Survival Rates eMaxHealth.com
Cancer Consultants - Nursing Times
all 42 news articles »
Early screening is crucial to improving recovery rates for breast ...
Orlando Sentinel, FL -
"What we worry about most is development of another breast cancer or the risk of this cancer coming back in your liver or bones," Shah says. ...

HealthNews
Bayer's Nexavar sales warm Onyx
Bizjournals.com, NC - Jul 30, 2008
Nexavar was approved as a liver cancer treatment by Japanese regulators in January. Onyx receives a single-digit royalty from Bayer on Nexavar sales there. ...
Liver Cancer Drug Gains Approval in China HealthNews
Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty ... PR Newswire (press release)
all 26 news articles »  ONXX - BAC
Source: Google News

HBx gene of hepatitis B virus induces liver cancer in transgenic mice -
CM Kim, K Koike, I Saito, T Miyamura, G Jay - Nature, 1991 - nature.com
HBx gene of hepatitis B virus induces liver cancer in transgenic mice. ... THE exact
role of hepatitis B virus in the development of liver cancer is not known. ...

… , and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous … -
BZ Yuan - Cancer Research, 1998 - AACR
... DLC-1 may be a tumor suppressor gene in liver cancer as well as in other cancers.
This article has been cited by other articles: (Search Google Scholar for ...

High-intensity focused ultrasound in the treatment of experimental liver cancer -
R Yang, CR Reilly, FJ Rescorla, PR Faught, NT … - Archives of Surgery, 1991 - Am Med Assoc
... High-intensity focused ultrasound in the treatment of experimental liver cancer.
R. Yang, CR Reilly, FJ Rescorla, PR Faught, NT Sanghvi ...

Functional inactivation but not structural mutation of p 53 causes liver cancer -
H Ueda, SJ Ullrich, JD Gangemi, CA Kappel, L Ngo, … - Nature Genetics, 1995 - nature.com
... Kim, CM, Koike, K., Saito, I., Miyamura, T. & Jay, G., The HBx gene of hepatitis
B virus induces liver cancer in transgenic mice. ... Cancer Res ... Search buyers guide ...

Global Cancer Statistics, 2002 -
DM Parkin, F Bray, J Ferlay, P Pisani - CA: A Cancer Journal for Clinicians, 2005 - Am Cancer Soc
... 1 million); the most common causes of cancer death are lung cancer (1.18 million
deaths), stomach cancer (700,000 deaths), and liver cancer (598,000 deaths). ...

Excess Risk of Primary Liver Cancer in Patients With Diabetes Mellitus -
HO Adami, WH Chow, O Nyren, C Berne, MS Linet, A … - jnci, 1996 - jnci.oxfordjournals.org
... 88, No. 20, 1472-1477, October 16, 1996 ? 1996 Oxford University Press Excess
Risk of Primary Liver Cancer in Patients With Diabetes Mellitus. ...

PUBLIC HEALTH: Reducing Liver Cancer--Global Control of Aflatoxin -
SH Henry, FX Bosch, TC Troxell, PM Bolger - Science, 1999 - sciencemag.org
... Search PubMed for: ... Policy Forum. PUBLIC HEALTH: Reducing Liver Cancer--Global
Control of Aflatoxin. Sara Hale Henry, F. Xavier Bosch ...

Detection of Aberrant p16 Methylation in the Plasma and Serum of Liver Cancer Patients 1 -
IHN Wong, YM Dennis Lo, J Zhang, CT Liew, MHL Ng, … - Cancer Research, 1999 - AACR
... Search PubMed for articles by: Wong, IHN || Johnson ... 1, 1999] ? 1999 American Association
for Cancer Research ... in the Plasma and Serum of Liver Cancer Patients 1. ...

Report of the 15th follow-up survey of primary liver cancer -
I Ikai, Y Itai, K Okita, M Omata, M Kojiro, K … - Hepatology Research, 2004 - Elsevier
... Quick Search Title, abstract, keywords Author eg js smith Search tips (Opens new
window) Journal ... Report of the 15th follow-up survey of primary liver cancer. ...

Hepatitis Bx antigen in hepatitis B virus carrier patients with liver cancer -
WL Wang - Cancer Research, 1991 - AACR
... of primary liver cancers. This article has been cited by other articles: (Search
Google Scholar for Other Citing Articles). Home page, Clin Cancer Res Home page ...

Source: Google Scholar

Advance In The Search For An Effective Treatment For Liver Cancer
Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics. Using a newly available monoclonal antibody, they demonstrated significant reductions in tumor cell proliferation and survival in human and mouse hepatocellular cancer (HCC) cell lines. According to the researchers, this finding has significant implications not only for the treatment of liver cancer but for a number of different types of cancer.

Most cases of HCC are secondary to either a viral hepatitis infection or cirrhosis of the liver. Despite recent advances, it remains a disease of grim prognosis due to the poorly understood mechanism of how the disease originates and spreads. Most patients live only a short time after diagnosis.
Based on previous studies showing that some pathways that were previously thought to be active only during fetal liver development, particularly the class III receptor tyrosine kinase (RTK) family pathway, became highly active again in the liver of HCC patients, Satdarshan P. Singh Monga, M.D., associate professor, division of cellular and molecular pathology and colleagues at the University of Pittsburgh School of Medicine, obtained rat and human liver cancer cell lines and analyzed them for level of expression of an RTK protein known as platelet-derived growth factor receptor-alpha, or PDGFR'. The investigators also analyzed the cells for their level of activation of the PDGFR' gene.

At an early fetal stage of liver development in the mouse, the investigators found that the level of expression of PDGFR' was 37 times higher compared to later stages of development in the adult mouse liver. They also found significantly higher levels of PDGFR' in rat and human liver cancer cell lines as compared to normal cells in culture.

Dr. Monga's group then treated human and mouse liver cancer cell lines with a monoclonal antibody targeted against PDGFR'. It resulted in a significant decrease in tumor cell proliferation and a marked increase in tumor cell death. In fact, all tumor cell lines experienced significant decreases in proliferation in response to the monoclonal antibody and there was a 4- to 18-fold increase in programmed cell death, or apoptosis, among the cancer cell lines compared to normal control cells.

According to Dr. Monga, these results suggest that PDGFR' offers an important new therapeutic target for the treatment of HCC.

"We are very excited because this is the first targeted therapy for liver cancer. Other therapies have some modest benefits, but no one knows exactly how they work. We now have identified a pathway that appears to be overly active in more than 70 percent of the cancers we examined and, when targeted, leads to significant reduction in tumor cell proliferation and survival," said Dr. Monga.
More importantly, targeting the PDGFR' pathway in liver cancer cells does not appear to affect normal liver cells, making the treatment relatively non-toxic. "Normally, regenerating liver cells are not exclusively dependent on this pathway, and it is not overly active in other types of cells. So this monoclonal antibody is a highly targeted treatment for this disease," he added.

Furthermore, because high expression of PDGFR' has been detected in a variety of tumors, such as skin cancer, brain tumors, gastrointestinal tumors, prostate tumors, ovarian cancer and leukemia, Dr. Monga believes these findings could have much broader applications.

This research was funded by grants from the American Cancer Society and the National Institutes of Health as well as the Cleveland Foundation and the Rango's Fund for Enhancement of Pathology Research.

In addition to Dr. Monga, other researchers involved in the study included Peggy Stock, Xinping Tan and Amanda Micsenyi, all in the department of pathology, University of Pittsburgh School of Medicine; Dulabh Monga, department of human oncology, Allegheny General Hospital, Pittsburgh; and Nick Loizos, ImClone Systems, Inc., New York.

Source: Jim Swyers
University of Pittsburgh Schools of the Health Sciences
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.